Träger des Paul-Martini-Preises

2024

Prof. Dr. med. Michael Platten (Mannheim/Germany)

2023

Prof. Dr. med. Andrea Ablasser (Lausanne/Switzerland)

2022

Prof. Dr. med. Stefan Fröhling (Heidelberg/Germany)
Prof. Dr. med. Hanno Glimm (Dresden/Germany)

2021

Prof. Dr. Dr. med. Thomas Thum (Hannover/Germany)

2020

Prof. Dr. Peter Kühnen (Berlin/Germany)

2019

Prof. Dr. med. Robert Zeiser (Freiburg/Germany)

• Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD mutant leukemia cells. (Nature Medicine, 2018)
• Oncogenic JAK2V617F causes PD-L 1 expression mediating immune-escape in myeloproliferative neoplasms. (Science Translational Medicine, 2018)
• Neutrophils provide cellular communication between ileum and mensenteric lymph nodes at graft-versus-host disease onset. (Blood, 2018)

2018

Prof. Dr. med. Thorsten Zenz (Zürich/Switzerland)

• Recurrent CDKN1B (p27) mutations in hairy cell leukemia (Blood, 2015)
• BRAF inhibition in hairy cell leukemia with low-dose vemurafenib (Blood, 2016)
• Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations (Blood, 2017)
• Drug-perturbation-based stratification of blood cancer (Journal of Clinical Investigation, 2018)

2017

Prof. Dr. med. Harald Renz (Marburg/Germany)
Prof. Dr. rer. nat. Holger Garn (Marburg/Germany)

• Allergen-Induced Asthmatic Responses Modified by a GATA3-Specific DNAzyme (New Engl J Med)

2016

Dr. med. Jan Krönke (Ulm/Germany)

• Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells (Science 2014).
• Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS (Nature 2015).

2015

Prof. Dr. med. Sonja Schrepfer (Hamburg/Germany)

• Dichloroacetate prevents restenosis in preclinical animal models of vessel injury (Nature 2014).
• SCNT-derived ESCs with mismatched mitochondria trigger an immune response in allogeneic hosts (Cell Stem Cell 2014)
• Inducing myointimal hyperplasia versus atherosclerosis in mice: An introduction of two valid models (Journal of Visualized Experiments 2014).
• Human internal mammary artery (IMA) transplantation and stenting: a human model to study the development of in-stent restenosis (Journal of Visualized Experiments 2012).

2014

Prof. Dr. med. Matthias Tschöp (Munich/Germany)

• Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys and humans. (Science Translational Medicine 2013)
• Duodenal nutrient exclusion improves metabolic syndrome and stimulates villus hyperplasia. (Gut 2013)
• GLP-1R agonism enhances adjustable gastric banding in diet-induced obese rats. (Diabetes 2013)
• Targeted estrogen delivery reverses the metabolic syndrome. (Nature Medicine 2012)

2013

Prof. Dr. med. Andreas Engert (Cologne/Germany)

• Reduced treatment intensity in patients with early stage Hodgkin's lymphoma. (New England Journal of Medicine 2010)
• Reduced intensity of chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial. (The Lancet 2012)
• Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. (Journal of Clinical Oncology 2010)
• Brentuximab vedotin for relapsed or refractory CD30-positive hematologic malignancies – the GHSG experience. (Blood 2012)

2012

PD Dr. med. Jan Wehkamp (Stuttgart/Germany)

• Reduction of disulphide bonds unmasks potent antimicrobial activity of human ß-defensin 1 (Nature 2011)

Prof. Dr. med. Stephan Stilgenbauer (Ulm/Germany)
Prof. Dr. med. Michael Hallek (Köln/Germany)

• Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial (The Lancet 2010)

2011

PD Dr. med. Kaan Boztug (Wien/Austria)
Prof. Dr. med. Christoph Klein (München/Germany)

• Stem-Cell Gene Therapy for the Wiskott-Aldrich Syndrome (New England Journal of Medicine 2010;363:1918-27)

2010

PD Dr. med. Jürgen Ruland

• Adjuvanticity of a synthetic cord factoranalogue for subunit Mycobacterium tuberculosis vaccination requires FcRy-Syk–Card9–dependent innate immune activation (Journal of Experimental Medicine 2009)
• Inhibition of MALT1 protease activity is selectively toxic for activated B cell–like diffuse large B cell lymphoma cells (Journal of Experimental Medicine 2009)
• Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence (Nature 2009)
• Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin- 1ß production (Nature Immunology 2010)

Prof. Dr. med. Veit Hornung

• Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization (Nature Immunology 2008)
• AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC (Nature 2009)
• RIG-I-dependent sensing of Poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate (Nature Immunology 2009)
• Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin-1ß production (Nature Immunology 2010)